Sequenom 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 19, 2012
(Exact Name of Registrant as Specified in Charter)
3595 JOHN HOPKINS COURT
SAN DIEGO, CALIFORNIA 92121
(Address of Principal Executive Offices)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Sequenom Center for Molecular Medicine, LLC (Sequenom CMM), our wholly-owned subsidiary, entered into an amendment (the Amendment) to its MPI Participating Ancillary Agreement with MultiPlan, Inc., dated May 1, 2010 (the MultiPlan Agreement). The Amendment amends the MultiPlan Agreement to provide, among other things, that Sequenom CMMs MaterniT21 PLUS laboratory-developed test is a covered service under the MultiPlan Agreement, subject to the conditions set forth therein.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.